MGMT promoter methylation and glioblastoma: A comparison of analytical methods and of tumor specimens

International Journal of Biological Markers

Volumn 30, Issue 2, 2015, Pages e208-e216

  Lattanzio, Laura ^a   Borgognone, Marzia ^a   Mocellini, Cristina ^a   Giordano, Fabrizio ^a   Favata, Ermanno ^a   Fasano, Gaetano ^a   Vivenza, Daniela ^a   Monteverde, Martino ^a   Tonissi, Federica ^a   Ghiglia, Annalisa ^a   Fillini, Claudia ^a   Bernucci, Claudio ^a   Merlano, Marco ^a   Nigro, Cristiana Lo ^a  

^a S Croce City Hospital   (Italy)

Author keywords

FFPE tissue; Frozen tissue; Methylation specific PCR; MGMT methylation; Pyrosequencing

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; METHYLATION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; BRAIN TUMOR; DNA METHYLATION; GENETICS; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84934766350     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000126     Document Type: Article

References (31)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2): 97-109.
2. Stupp R, Mason WP, van den Bent MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.
3. Zhang K, Wang XQ, Zhou B, Zhang L. The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis. Fam Cancer. 2013; 12(3): 449-458.
4. Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012;23(2): 307-322, ix.
5. Christians A, Hartmann C, Benner A, et al. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS ONE. 2012; 7(3): e33449.
6. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn. 2007; 9(3): 368-381.
7. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25): 4189- 4199.
8. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol. 2009; 64(4): 647-655.
9. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004; 10(15): 4933-4938.
10. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59(4): 793-797.
11. Herfarth KK, Brent TP, Danam RP, et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 1999; 24(2): 90-98.
12. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19): 1350-1354.
13. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003.
14. Frommer M, McDonald LE, Millar DS, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA. 1992; 89(5): 1827-1831.
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996; 93(18): 9821-9826.
16. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997; 25(12): 2532-2534.
17. Ronaghi M, Uhlén M, Nyrén P. A sequencing method based on real-time pyrophosphate. Science. 1998; 281(5375): 363- 365, 365.
18. El-Maarri O, Herbiniaux U, Walter J, Oldenburg J. A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res. 2002; 15;30: e25.
19. Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005; 33(14): e128.
20. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine- DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008; 10(4): 332-337.
21. Mellai M, Caldera V, Annovazzi L, et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics Proteomics. 2009; 6(4): 219-227.
22. Håvik AB, Brandal P, Honne H, et al. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med. 2012; 10 (1): 36.
23. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13): 2192-2197.
24. Weller M, Stupp R, Reifenberger G, et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010; 6(1): 39-51.
25. Quillien V, Lavenu A, Karayan-Tapon L, et al. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylationsensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer. 2012; 118(17): 4201-4211.
26. Tournier B, Chapusot C, Courcet E, et al. Why do results conflict regarding the prognostic value of the methylation status in colon cancers? The role of the preservation method. BMC Cancer. 2012; 12(1): 12.
27. Shaw RJ, Akufo-Tetteh EK, Risk JM, Field JK, Liloglou T. Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res. 2006; 34(11): e78.
28. Hamilton MG, Roldán G, Magliocco A, McIntyre JB, Parney I, Easaw JC. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme. J Neurooncol. 2011; 102(2): 255-260.
29. Della Puppa A, Persano L, Masi G, et al. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients? J Neurooncol. 2012; 106(1): 33-41.
30. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. J Clin Oncol. 2009; 27(8): 1275-1279.
31. Fiano V, Trevisan M, Trevisan E, et al. MGMT promoter methylation in plasma of glioma patients receiving temozolomide. J Neurooncol. 2014; 117(2): 347-357.